Progress in survival following three decades of allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: A real‐world registry study in Japan

医学 移植 骨髓增生异常综合症 内科学 国际预后积分系统 造血细胞 移植物抗宿主病 造血干细胞移植 肿瘤科 骨髓 造血 干细胞 生物 遗传学
作者
Takaaki Konuma,Hidehiro Itonaga,Ken Ishiyama,Atsushi Hamamura,Naoyuki Uchida,Yukiyasu Ozawa,Yuta Katayama,Masatoshi Sakurai,Yasunori Ueda,Ken‐ichi Matsuoka,Toshiro Kawakita,Tetsuya Eto,Takahide Ara,Junya Kanda,Makoto Onizuka,Takahiro Fukuda,Yoshiko Atsuta
出处
期刊:American Journal of Hematology [Wiley]
卷期号:98 (4) 被引量:10
标识
DOI:10.1002/ajh.26839
摘要

Allogeneic hematopoietic cell transplantation (HCT) can eradicate myelodysplastic syndrome (MDS) clones through high-dose chemoradiotherapy and the graft-versus-tumor effect,1 and it remains the only potentially curative treatment modality for MDS. Although the improvement of transplant procedures, such as advanced supportive care and increased availability of unrelated donors, has resulted in progressive outcomes over time after allogeneic HCT,2-4 the results for trends of transplant outcomes have been unclear for adult patients with MDS. Here, we investigated the trends in outcomes after allogeneic HCT for unselected adult MDS patients in Japan. Details for methods are provided in the supplemental methods (Data S1). We identified 6257 adult patients with MDS who received their first allogeneic HCT between 1987 and 2020. Among them, 550, 1954, and 3753 patients were transplanted in 1987–2000, 2001–2010, and 2011–2020, respectively. Over the three time periods, there was a progressive increase in age at HCT, male recipients, poor karyotype, high-risk at HCT, diagnosis of HCT <6 months, unrelated donor, HLA mismatch, and graft-versus-host disease (GVHD) prophylaxis with methotrexate (Table S1). The absolute annual numbers of HCT for age ≥60 years increased substantially over time, from 1 (1.9%) in 1997 to 245 (51.0%) in 2020 (Figure 1A). The absolute annual number of unrelated bone marrow transplantation (UBMT) has increased since 2004. More recently, the increase in unrelated cord blood transplantation (UCBT) was remarkable, from 1 (1.2%) in 1999 to 158 (32.9%) in 2020 (Figure 1B). As for conditioning intensity, both myeloablative conditioning (MAC) and reduced-intensity conditioning have increased over time, but MAC has been more commonly performed in all periods (Figure 1C). The unadjusted probability of overall survival (OS) was not significant across the time periods (Figure 1D), whereas the unadjusted probability of disease-free survival (DFS) had significantly deteriorated between the time periods (Figure 1F). However, multivariate analyses showed that OS and DFS were significantly improved across the time periods (Table S2). The adjusted probabilities of OS and DFS improved over time (Figure 1E,G). The unadjusted cumulative incidence of relapse deteriorated between the time periods (Figure 1H). In the multivariate analysis, the relapse rate was not significantly associated with the time periods. The adjusted cumulative incidence of relapse was not improved across the time periods (Figure 1I). The unadjusted cumulative incidence of non-relapse mortality (NRM) had significantly improved between the time periods (Figure 1J). Multivariate analyses showed that NRM was significantly improved across the time periods (Table S2). The adjusted cumulative incidence of NRM improved over time (Figure 1K). The most common cause of death was an infection in the first two time periods, but it was relapse or progression of MDS in the most recent period (Table S3). Thus, the proportion of deaths from relapse or progression of MDS increased in a stepwise fashion. Although the proportion of deaths from GVHD, pulmonary complication, organ failure, and hemorrhage decreased in the latter two time periods, the proportion of death from infection was not different across the three time periods. Subgroup analyses showed that OS and DFS had significantly improved over time based on age, disease risk at HCT, donor type, and conditioning intensity, except that OS and DFS did not improve among patients aged 40–59 years and those with low risk at HCT (Figure S1, Table S4). An important finding in our study was that the risk of relapse or progression of MDS after allogeneic HCT has gradually increased over time, and the proportion of death from relapse or progression of MDS has increased in a stepwise fashion. Such an increment of relapse or progression could have arisen because of the increased proportions over time of patients with advanced diseases, such as high-risk at HCT and poor karyotype. Therefore, to reduce the disease burden before allogeneic HCT, induction chemotherapy and hypomethylating agents have been tried in some patients with a higher disease burden. Indeed, the main change in clinical practice during the study period has been the introduction of azacytidine since 2011 in Japan. However, consistent with previous studies,5, 6 our study showed that the relapse rates and mortality did not improve in high-risk patients who received pre-transplant induction chemotherapy and hypomethylating agents compared to those who did not receive them, regardless of transplant year (Figure S2). This may reflect the selection bias that derives from the inclusion of patients with advanced diseases who received pre-transplant induction chemotherapy and hypomethylating agents. However, these pre-transplant treatments could be useful as a bridging therapy to allogeneic HCT that aims to avoid disease progression among patients with high disease burden. Furthermore, post-transplant maintenance strategies using several targeting agents might be beneficial, but their effects remain elusive for the further reduction of relapse or progression of MDS after allogeneic HCT.7 Importantly, a reduction of relapse rate will be needed for the further improvement of allogeneic HCT for MDS. The improvement in survival over time primarily resulted from decreased NRM among MDS patients. This result could be encouraging despite increased indications for older patients and more frequent use of unrelated donors over time. The proportions of death from GVHD, pulmonary complications, organ failure, and hemorrhage decreased in the latter two time periods, but those from infection did not decrease across the three time periods. These findings indicate that the prevention and management of GVHD, pulmonary complications, organ failure, and hemorrhage might be adequate, which is consistent with previous studies,2, 3 but the management of carryover infection, partly due to prolonged neutropenia during the pretransplant phase, might remain insufficient after allogeneic HCT for MDS. Therefore, stricter prevention and treatment of infectious complications could be required for further improvement of NRM after allogeneic HCT for MDS patients. Recently, the BMT CTN 1102 study has prospectively confirmed a survival benefit of allogeneic HCT over non-HCT therapy in high-risk MDS up to the age of 75 years.8 Furthermore, several studies have suggested that allogeneic HCT is a viable option for patients aged 60 or older.9-13 Indeed, a remarkable change in patients' characteristics over time in our cohort was the progressive increase in older patients. In particular, the proportion of patients aged 60 years older drastically increased from 1.9% in 1997 to 51.0% in 2020, and the absolute annual numbers of HCT for age ≥70 years also increased over time, from 2 (1.6%) in 2000 to 34 (7.0%) in 2020 (Figure S3A), which could have contributed to no improvement of unadjusted OS and DFS over time. Although previous studies showed that chronological age did not significantly affect post-transplant survival of adult patients including those with MDS,9-11 our study demonstrated that older patients aged ≥60 years had significantly poorer transplant outcomes, whereas younger patients aged <40 years had significantly better transplant outcomes. Thus, chronological age remains an important prognostic factor for allogeneic HCT for adult patients with MDS. However, recent encouraging reports have demonstrated the efficacy and safety of allogeneic HCT in selected patients aged ≥70 years.13 Therefore, chronological age alone should not exclude an elderly patient as a candidate for allogeneic HCT, but optimal strategies for pretransplant risk assessment in elderly patients, such as geriatric assessment, will be needed for the better selection of older adults with MDS. The marked increase in the number of UBMT and UCBT in our cohort could have overcome the donor unavailability for MDS patients to facilitate allogeneic HCT, particularly in the latter two time periods. Although survival was significantly worse in patients who received UBMT and UCBT compared to those who received related BMT during the entire study period in the multivariate analysis, OS was improved in the latter two time periods (2001–2010, 2011–2020) than in the earlier period (1987–2000) among patients who received UBMT. Among patients who received UCBT, a drastic improvement of OS was observed in the most recent time period (2011–2020) compared to those in the middle time period (2001–2010), which is consistent with our previous reports of UCBT for adult AML and various hematological diseases.3, 4 Surely, matched sibling donor (MSD) has remained a frontline donor source followed by matched unrelated donor or unrelated cord blood for MDS, but a recent study by the European Group for Blood and Marrow Transplantation demonstrated higher DFS after allogeneic HCT for MDS using younger matched unrelated donors compared with older MSDs.14 Furthermore, rapid availability is the most important benefit for alternative HLA mismatched donors, such as unrelated cord blood or a haploidentical related donor,15, 16 for MDS patients, because some patients needed an urgent allogeneic HCT (Figure S3B). This ease of donor availability could extend access to allogeneic HCT for MDS because the identification of an MSD can be limited for patients with MDS, particularly in the elderly. In conclusion, our data could provide valuable evidence for allogeneic HCT for MDS patients in a real-world setting. Survival and NRM have improved after allogeneic HCT for adult patients with MDS, but a reduction of relapse rate will remain a challenge for further improvement. We thank all of the physicians and staff at the centers who provided the clinical data to the Transplant Registry Unified Management Program of the Japanese Data Center for Hematopoietic Cell Transplantation and the Japanese Society for Transplantation and Cellular Therapy (JSTCT). This work was supported in part by the Practical Research Project for Allergic Diseases and Immunology (Research Technology of Medical Transplantation) from Japan Agency for Medical Research and Development, AMED, under Grant Number 18ek0510023h0002. The authors declare no competing financial interests, except that MS received research support from Nippon Shinyaku and owns stock in Celaid Therapeutics. The data that support the findings of this study are available from the corresponding author upon reasonable request. Figure S1. Figure S2. Figure S3. Supplementary Table S1. Patient characteristics. Supplementary Table S2. Multivariate analysis of overall mortality, treatment failure, relapse, and non-relapse mortality. Supplementary Table S3. Cause of death according to time periods. Supplementary Table S4. Subgroup analysis of adjusted hazard ratio of overall mortality and treatment failure. Data S1. Supporting Information. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李爱国应助kent采纳,获得10
1秒前
yy14207发布了新的文献求助10
1秒前
笨笨的秋发布了新的文献求助10
2秒前
2秒前
2秒前
科研通AI2S应助Espionage采纳,获得10
2秒前
2秒前
3秒前
4秒前
mascot0111完成签到,获得积分10
4秒前
5秒前
ykiiii发布了新的文献求助10
6秒前
洋芋儿发布了新的文献求助20
7秒前
7秒前
道松先生发布了新的文献求助10
7秒前
泽言发布了新的文献求助30
7秒前
梦在彼岸完成签到,获得积分10
8秒前
9秒前
李爱国应助yijiang采纳,获得10
10秒前
小橙子发布了新的文献求助10
11秒前
yzx完成签到,获得积分10
11秒前
咸的豆包儿完成签到,获得积分10
11秒前
yy14207发布了新的文献求助20
11秒前
森花完成签到,获得积分10
12秒前
Jasper应助Dr.c采纳,获得10
12秒前
12秒前
zkwgly完成签到,获得积分10
14秒前
打打应助宋宋采纳,获得10
14秒前
14秒前
15秒前
x123完成签到,获得积分10
15秒前
动次打次完成签到,获得积分0
15秒前
RPG完成签到,获得积分10
16秒前
zkwgly发布了新的文献求助10
17秒前
量子星尘发布了新的文献求助10
18秒前
18秒前
小马甲应助XLL小绿绿采纳,获得10
19秒前
赫灵竹完成签到,获得积分10
20秒前
lalafish发布了新的文献求助10
21秒前
退没发布了新的文献求助10
22秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3972199
求助须知:如何正确求助?哪些是违规求助? 3516694
关于积分的说明 11184114
捐赠科研通 3252015
什么是DOI,文献DOI怎么找? 1796253
邀请新用户注册赠送积分活动 876326
科研通“疑难数据库(出版商)”最低求助积分说明 805477